Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia

Hyperlipoproteinemia Type III Clinical Trial

— EVOLVE-FD  

Official title:

A Multicenter, Randomized, Double-blind, Placebo-controlled, Crossover Trial to Evaluate the Effects of Evolocumab Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03811223
• Other study ID #: UMCU-VASC-CO-002
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: August 2019
• Est. completion date: March 2021

Study information

• Verified date: January 2019
• Source: UMC Utrecht
• Contact: Frank LJ Visseren, prof
• Phone: +31 88 7557324
• Email: f.l.j.visseren[@]umcutrecht.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with familial dysbetalipoproteinemia (FD) have increased triglycerides, non-high-density lipoprotein cholesterol (non-HDL-C), beta VLDL, premature atherosclerosis and cardiovascular disease. They also have a delayed postprandial triglyceride and chylomicron (CM) remnant clearance. Postprandial hypertriglyceridemia is associated with increased vascular risk. Although combination therapy with statin and fibrate is recommended in the treatment of patients with FD, there is still a substantial amount of patient who do not reach their treatment target with this medication. Furthermore no information is available about the postprandial effects of adding evocolumab to standard lipid lowering therapy in FD patients.

Description:

See brief summary

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: March 2021
• Est. primary completion date: January 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

1. Patients diagnosed with Familial Dysbetalipoproteinemia;

• e2e2 genotype or dominant APOE mutation genotype (confirmed by genotyping or isoelectric focusing) with any lipid-lowering treatment at a stable dose for at least three months and non-HDL-C >1.6 mmol/L or;

• Patients with e2e2 genotype or dominant APOE mutation (confirmed by genotyping or isoelectric focusing) without lipid-lowering treatment and with an ApoB/TC ratio < 0.15.

2. >18 years old (on the day of signing informed consent).

3. Women are postmenopausal and not receiving hormone therapy (including cyclic and non-cyclical hormone replacement therapy or any estrogen antagonist/agonist). Postmenopausal status is defined as:

• no menses for =3 years or;

• no menses for =1 year but <3 years and confirmed by FSH levels elevated into the postmenopausal range (15-150 IU/L).

4. Willingness to maintain a stable diet for the duration of the study.

5. Understanding of the study procedures, alternative treatments available, and risks involved with the study and voluntarily agreement to participate by giving written informed consent.

Exclusion criteria:

1. Intolerance, known allergy or hypersensitivity to evolocumab (or other PCSK-9 monoclonal antibodies), latex or any of the components of the medication.

2. Current or prior exposure to evolocumab or another PCSK9-inhibitor mAb in the past 12 weeks.

3. Unable or unwilling to drink an oral fat load.

4. Premenopausal women.

5. Uncontrolled diabetes as defined by a HbA1c >69 mmol/mol.

6. BMI >40 kg/m2.

7. Uncontrolled blood pressure with systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg.

8. Increased hepatic enzymes, defined as alanine transaminase (ALAT) or aspartate transaminase (ASAT) >3 times the ULN, or active liver disease defined as non alcoholic steatohepatitis (NASH), cirrhosis or Child Pugh B and C, or history of chronic active hepatitis B or C; subjects with documented resolution after treatment are permitted.

9. Impaired renal function, defined by an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2, and/or need of renal placement therapy or other clinically significant renal disease.

10. (Sub)clinical hypothyroidism defined as TSH >5.0 mcl/U/mL or (sub)clinical hyperthyroidism defined as TSH < 0.35 mcl/U/ml.

11. Increased levels of creatinine kinase defined as >3 times the ULN.

12. Increased fasting levels of triglycerides defined as >10 mmol/L.

13. History of organ transplantation and/or use of immunosuppressive medication.

14. Use of fish oil or red yeast rice, bempedoic acid, niacin, CETP inhibitors, lomitapide, mipomersen < 6 weeks prior to the study or the use of siRNA targeting PCSK9 inhibitors < 36 weeks prior to the study.

15. Active malignancy (<2 year prior to informed consent), except non-melanoma skin cancer or carcinoma in situ of the cervix.

16. Known infection with Human Immunodeficiency Virus (HIV) or AIDS.

17. Known celiac disease or other disorder associated with significant intestinal malabsorption.

18. Known galactose-intolerance, Lapp-lactase deficiency or glucose-galactose malabsorption.

19. Alcohol use, defined as >14 alcoholic consumptions per week for women and >21 alcohol consumptions per week for men. One alcohol consumption unit is defined as follows: 350 mL beer, 150 mL wine or 45 mL alcohol for mixed drinks.

20. Current participation or participation in a study with an investigational compound or device within 30 days of signing informed consent.

21. Any medical, social or physiological circumstance which interferes the study, based on judgement by the principal investigator.

Related Conditions & MeSH terms

• Familial Dysbetalipoproteinemia
• Hyperlipidemias
• Hyperlipoproteinemia Type III
• Hyperlipoproteinemias

Intervention

Drug:
• Evolocumab Auto-Injector [Repatha]
Evolocumab 140 mg every 2 weeks for 12 weeks
• Placebos
Placebo subcutaneous injection every 2 weeks for 12 weeks

Locations

Country	Name	City	State
n/a

Sponsors (4)

Lead Sponsor	Collaborator
UMC Utrecht	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Erasmus Medical Center, University Medical Center Nijmegen

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUC (area under the curve) non-HDL-cholesterol		12 weeks
Secondary	Fasting levels, AUC and iAUC of total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides and ApoB, as well as fasting non-HDL-cholesterol.		12 weeks
Secondary	Percentage change from baseline and absolute difference in fasting and post fat load non-HDL-cholesterol, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides and ApoB.		12 weeks
Secondary	Fasting and post fat load lipoprotein (VLDL1, VLDL2, IDL, LDL, HDL) concentrations and composition (triglycerides, cholesterol, ApoB and apolipoproteins).		12 weeks
Secondary	Post fat load ApoB 48-containing lipoprotein concentrations (chylomicrons and chylomicron remnants) and proteins involved in postprandial lipid metabolism.		12 weeks